The leukotriene B4 /BLT1-dependent neutrophil accumulation exacerbates immune complex-mediated glomerulonephritis

Ryotaro Shioda1,2, Airi Jo-Watanabe1,3, Toshiaki Okuno1

  • 1Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Insights

Leukotriene B4 (LTB4) and its receptor BLT1 drive neutrophil infiltration in crescentic glomerulonephritis. Targeting the LTB4-BLT1 pathway offers a promising therapeutic strategy for this kidney disease.

Area of Science:

  • Nephrology
  • Immunology
  • Pathology

Background:

  • Crescent formation is critical for nephritis prognosis.
  • Neutrophils are key in crescentic glomerulonephritis, but their chemoattractant is unknown.

Purpose of the Study:

  • Identify the key chemoattractant for neutrophils in glomerulonephritis.
  • Investigate the role of leukotriene B4 (LTB4) and its receptor BLT1 in disease pathogenesis.

Main Methods:

  • Used a mouse model of immune complex-mediated crescentic glomerulonephritis.
  • Analyzed neutrophil infiltration, LTB4 and BLT1 expression, and kidney injury markers.
  • Utilized genetic deficiency (BLT1/LTB4 knockout) and pharmacological inhibition (BLT1 antagonist).
  • Examined glomeruli from human ANCA-associated glomerulonephritis patients.

Main Results:

  • LTB4 and BLT1 were crucial for neutrophil accumulation and kidney injury.
  • Mice deficient in BLT1 or LTB4 showed reduced glomerulonephritis and fibrosis.
  • Early neutrophil depletion prevented kidney damage; BLT1 antagonist administration suppressed disease.
  • Increased BLT1-positive cells were found in human ANCA-associated glomerulonephritis glomeruli.

Conclusions:

  • The LTB4-BLT1 axis is a primary driver of neutrophilic glomerular inflammation.
  • This pathway represents a novel therapeutic target for crescentic glomerulonephritis.